Literature DB >> 240057

Renal secretion of diphosphonates in rats.

U Troehler, J P Bonjour, H Fleisch.   

Abstract

Diphosphonates, characterized by a P--C--P bond, are relatively new experimental drugs used for the treatment of myositis ossificans, dental calculus, nephrolithiasis and Paget's disease. These compounds are not metabolized and the fraction which is not taken up by the skeleton is excreted unchanged in the urine. In the present study, the renal clearances of two 14C-labelled diphosphonates, disodium ethane-1-hydroxy-1,1-diphosphonate (CEHDP) and disodium dichloromethylene diphosphonate (CC12MDP) have been measured in conscious rats. The clearances have been found to be higher than the glomerular filtration rate (GFR), Cdiphosphonate/GFR being about 1.5. This observation indicates net tubular secretion of both drugs. High plasma concentration of EHDP or Cl2MDP significantly depressed CEHDP, whereas CEHDP was not influenced by varying urine pH, by infusing NH4Cl or NaHCO3, or by simultaneous administration of high doses of para-aminohippurate (PAH), probenecid, N-methylnicotinamide or Ca-EDTA. High plasma concentration of inorganic phosphate depressed CEHDP and also depressed the in vitro ultrafiltrability of EHDP. In conclusion, these results provide evidence of an active renal transport of diphosphonates which appears distinct from the mechanisms handling organic acids, organic bases and EDTA in the rat kidney.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 240057     DOI: 10.1038/ki.1975.70

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  On the pharmacological evaluation of bisphosphonates in humans.

Authors:  Serge Cremers; Frank Hal Ebetino; Roger Phipps
Journal:  Bone       Date:  2020-06-27       Impact factor: 4.398

2.  Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.

Authors:  N Naganathar; W -P Yau; Z H Mok; Z Y F Tan; S T H Chew
Journal:  Osteoporos Int       Date:  2021-03-15       Impact factor: 4.507

Review 3.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 5.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

6.  Inorganic phosphate homeostasis. Renal adaptation to the dietary intake in intact and thyroparathyroidectomized rats.

Authors:  U Tröhler; J P Bonjour; H Fleisch
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

7.  Effect of diphosphonates on ATP and Pi content, Pi uptake and energy charge of cultured calvaria cells.

Authors:  R Felix; H Fleisch
Journal:  Experientia       Date:  1982-06-15

Review 8.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

9.  The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture.

Authors:  D K Fast; R Felix; C Dowse; W F Neuman; H Fleisch
Journal:  Biochem J       Date:  1978-04-15       Impact factor: 3.857

10.  The effect of pyrophosphate and diphosphonates on calcium transport in red cells.

Authors:  R Felix; H Fleisch
Journal:  Experientia       Date:  1977-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.